Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF THE SYNTHESIZED GROWTH-HORMONE RELEASING PEPTIDE, KP-102, ON GROWTH-HORMONE RELEASE IN SODIUM GLUTAMATE MONOHYDRATE-TREATED LOW GROWTH RATS
Autore:
NAKAGAWA T; UKAI K; OHYAMA T; KOIDA M; OKAMURA H;
Indirizzi:
KAKEN PHARMACEUT CO LTD,CENT RES INST,YAMASHIMA KU,14 SHINOMIYA KYOTO607 JAPAN SETSUNAN UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL OSAKA JAPAN KOBE UNIV,SCH MED,DEPT ANAT KOBE 650 JAPAN
Titolo Testata:
Life sciences
fascicolo: 9, volume: 59, anno: 1996,
pagine: 705 - 712
SICI:
0024-3205(1996)59:9<705:EOTSGR>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
(GHRP-6)-INDUCED GH SECRETION; HYPOTHALAMOPITUITARY DISCONNECTION; SOMATOSTATIN; HEXAPEPTIDE; GHRP-6;
Keywords:
KP-102; GROWTH HORMONE RELEASING PEPTIDE; ARCUATE NUCLEI LESION; ICV;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
T. Nakagawa et al., "EFFECTS OF THE SYNTHESIZED GROWTH-HORMONE RELEASING PEPTIDE, KP-102, ON GROWTH-HORMONE RELEASE IN SODIUM GLUTAMATE MONOHYDRATE-TREATED LOW GROWTH RATS", Life sciences, 59(9), 1996, pp. 705-712

Abstract

KP-102 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2), a new second generation hexapeptide, has a potent growth hormone (GH)-releasing action in vivo and in vitro. Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats. The plasma GH level in NMSG-LG rats after i.v. administration of KP-102 at 100 mu g/kg was 1/6.7 (95% C.L. 1/14.7 - 1/3.0) of that in normal rats given the same dose (p<0.01). However, the increase was significant compared with that in normal rats after saline administration (p<0.01). The plasma GH releasing action of KP-102 at 100 mu g/kg i.v. in rats with lesions in thebilateral hypothalamic arcuate nuclei (ARC), was about 1/6.3 (95% C.L. 1/12.4 - 1/3.2) of that in normal rats under PB anesthesia(p<0.01). When KP-102 was injected into the ARC at doses of 0.0002, 0.02 and 2 mu g/rat, GH release was dose-related (p<0.01) under PB anesthesia. KP-102 at 2 mu g i.c.v. also increased the plasma GH levels (p<0.01) to about 1/8.3 (95% C.L. 1/22.7 - 1/3.1) of that by systematic administration, at the same potency as the ARC injection (1/13.7 and 95% C.L. 1/37.2 - 1/5.0). These findings suggest that KP-102 potently stimulates the GH release by a direct or indirect antagonism of somatostatin (SRIF) and growth hormone releasing hormone (GHRH) release in the hypothalamus and by a direct action on the pituitary. Furthermore, the GH-releasing action of KP-102 was similar and additive upon both regions in vivo at the maximum effective dose. Moreover, since the GH-release in response to KP-102 administration differed between NMSG-LG and normal rats, and since KP-102 increased the GH release even in NMSG-LG rats, itshould be evaluated in the hypophysial GH secretion tests, and may beused to treat the hypophysial GH secretion insufficiency.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 09:46:00